Momentum Bioscience on sepsis

Momentum Bioscience is focused on developing rapid tests for patients suspected of sepsis.

Our patented ETGA® technology allows the universal detection of viable organisms in normally sterile samples such as blood. When ETGA® is combined with our innovative, microbial cell and circulating free DNA capture methods, we can provide a rapid, highly sensitive, actionable Gram positive and/or Gram negative and yeast discrimination.

Now incorporated into MagRapid, this test determines presence or absence of viable organisms together with a Gram category from 5mL whole blood in under 3 hr. With a limit of detection of <5 CFU/mL, MagRapid will be able to provide clinically actionable results earlier than blood culture. This will have a significant impact on the management of antibiotics and help mitigate the problem of increasing antimicrobial resistance.

MagRapid is designed to be run on instruments already established in the clinical laboratory and Momentum is seeking partners for joint commercialisation.


More about


Other news

Upcoming Events

BSA Annual Conference 2019: Translating Research into Practice

Molineux Stadium, Wolverhampton
Wednesday 5th June

Sepsis + Conference 2019

National Conference Centre Birmingham
11th June

Knowlex: Patient Safety 2019

NCC Birmingham
11th June 2019

BSG Annual Meeting 2019

Monday 17th June to Thursday 20th June 2019

AfPP Residential 2019

York University
8th to the 11th August

Latest Issue

Clinical Services Journal

Clinical Services Journal

May 2019

Improving safety for both staff and patients

Register now to apply for regular copies of Clinical Services Journal and free access to premium content, as well as our regular newsletters.

CSJ Supplements

CSJ Supplements

Apr 2019

Putting patients and hospitals first

Register now to apply for regular copies of CSJ Supplements and free access to premium content, as well as our regular newsletters.